U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7N6.Na
Molecular Weight 198.1604
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MK-0354 SODIUM

SMILES

[Na+].C1CC2=C(C1)C(=NN2)C3=NN=N[N-]3

InChI

InChIKey=WAEMBJUTNFWNNK-UHFFFAOYSA-N
InChI=1S/C7H7N6.Na/c1-2-4-5(3-1)8-9-6(4)7-10-12-13-11-7;/h1-3H2,(H-,8,9,10,11,12,13);/q-1;+1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H8N6
Molecular Weight 176.1786
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

MK-0354 is a GPR109a (Niacin receptor 1) agonist, originated by Arena Pharmaceuticals. In phase II of clinical trials against dyslipidemia treatment with MK-0354 failed to produce changes in high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, or triglycerides.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
505.0 nM [Kd]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
208 μM
2400 mg single, oral
MK-0354 plasma
Homo sapiens
373 μM
3600 mg 1 times / day multiple, oral
MK-0354 plasma
Homo sapiens
351 μM
3600 mg single, oral
MK-0354 plasma
Homo sapiens
147 μM
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens
235 μM
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
458 μM × h
2400 mg single, oral
MK-0354 plasma
Homo sapiens
766 μM × h
3600 mg 1 times / day multiple, oral
MK-0354 plasma
Homo sapiens
731 μM × h
3600 mg single, oral
MK-0354 plasma
Homo sapiens
392 μM × h
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens
457 μM × h
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.5 h
2400 mg single, oral
MK-0354 plasma
Homo sapiens
9.1 h
3600 mg 1 times / day multiple, oral
MK-0354 plasma
Homo sapiens
7.7 h
3600 mg single, oral
MK-0354 plasma
Homo sapiens
10.4 h
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens
9.9 h
1800 mg 2 times / day multiple, oral
MK-0354 plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
In a phase II study MK-0354 was administred daily at dose 2.5g for 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Equilibrium binding of [3H]nicotinic acid was done with membranes (30 μg/assay) from CHO-K1 cells, transfected with GPR109a, and test compound diluted in assay buffer (20 mM HEPES, pH 7.4, 1 mM MgCl2, and 0.01% CHAPS) in a total volume of 200 uL. After 4 h at room temperature, reactions were filtered through Packard Unifilter GF/C plates using a Packard Harvester and washed eight times with 200 μl of ice-cold binding buffer. Nonspecific binding was determined in the presence of 250 μM unlabeled nicotinic acid. Competitive binding assays were performed in the presence of 50 nM [3H]nicotinic acid.
Substance Class Chemical
Record UNII
LJM1M2YL86
Record Status Validated (UNII)
Record Version